Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
45 hedge funds and large institutions have $17.1M invested in Nymox Pharmaceutical Corp in 2017 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.
267% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 6
172% more capital invested
Capital invested by funds: $6.29M → $17.1M (+$10.8M)
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
55% more funds holding
Funds holding: 29 → 45 (+16)
80% less call options, than puts
Call options by funds: $842K | Put options by funds: $4.16M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.24M |
| 3 |
Morgan Stanley
New York
|
+$791K |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
+$307K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$305K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$851K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$156K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$140K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$84K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$51K |
NYMX Hedge Fund Activity: Q2 2017 in Review
45 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q2 2017, worth a combined $17.1M — up 172% from $6.29M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NYMX positions and 6 closed out — a net gain of 16 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $4.8M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $851K sold.
- 45 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q2 2017, up from 29 in Q1 2017.
- Funds reported $17.1M of Nymox Pharmaceutical Corp stock for Q2 2017, up 172% quarter-over-quarter.
- 22 funds opened new Nymox Pharmaceutical Corp positions in Q2 2017 and 6 closed out, a net change of +16 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q2 2017 was BlackRock, an estimated $4.8M added.
- The largest Nymox Pharmaceutical Corp seller in Q2 2017 was Susquehanna International Group, an estimated $851K sold.
Based on aggregated 13F filings for Q2 2017.